Fox Chase Cancer Center News

Physicians at Fox Chase Cancer Center have begun accepting patients for a new clinical trial looking at the effectiveness of a hepatic artery infusion (HAI) pump along with standard chemotherapy. Fox Chase is the only local hospital offering this trial, which is designed for patients with colorectal cancer that has spread to the liver and cannot be treated with surgery.

One hundred and forty-two Fox Chase Cancer Center physicians have been named to Philadelphia magazine’s “Top Doctors” list for 2025. Physicians on the list were nominated by a national survey of their professional peers.

The Cancer Epigenetics Institute (CEI) at Fox Chase Cancer Center will present new data at a workshop sponsored by biomodal, an omics-based life sciences technology and analytics company, during the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 25-30 in Chicago.

Fox Chase Cancer Center nurses Margaret Perri, BSN, RN, Elaine Spieller, BSN, RN, OCN, and Melissa Pfeifer, BSN, RN, presented a study at the Oncology Nursing Society (ONS) Congress highlighting the importance of educating inpatient nurses in community hospitals on best practices for treating oncologic emergencies.

Colbi Carr, BSN, RN, a nurse in the Clinical Research Thoracic Unit at Fox Chase Cancer Center, presented a study at the Oncology Nursing Society (ONS) Congress highlighting the importance of oncology clinical research rotations for undergraduate nursing programs.

Fox Chase Cancer Center nurses participated in presentations and discussions of a number of research projects at the 50th Annual Oncology Nursing Society Congress, which was held on April 9-13 in Denver.

PHILADELPHIA (April 3, 2025) — Histone lysine demethylases, or KDMs, were first documented in 2004 in a groundbreaking study that led to new understandings about the genetic mechanisms of cancer and other diseases. Now, researchers at Fox Chase Cancer Center have marked the 20th anniversary of this landmark discovery with a new paper in the prestigious journal Cell that reviews two decades of research and advances.

PHILADELPHIA (March 31, 2025) — Results from a study presented by Fox Chase Cancer Center researchers at the Society of Surgical Oncology 2025 Annual Meeting suggest that chemotherapy followed by local excision is a promising treatment option for patients with node-negative low rectal cancer.